2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1965

Association of HLA Class II Alleles with Relapse and Interstitial Lung Disease in Myeloperoxidsae (MPO) -ANCA Positive Vasculitis in a Japanese Population
Abstract Number: 1966

Transcriptome and Methylome Integrative Molecular Analysis Uncovers a New Systemic Autoimmune Disease Classification
Abstract Number: 1967

Detection of Association of Long Noncoding RNA ATP6V0E2-AS1 Single Nucleotide Polymorphism with Susceptibility to Myeloperoxidase-ANCA Associated Vasculitis Based on Transcriptome Analysis
Abstract Number: 1968

eQTL Analysis of More Than 1000 Human Blood Samples Reveals Shared and Unique Signals across Seven Systemic Autoimmune Diseases : The Precisesads Project
Abstract Number: 1969

GENE Enhancers Associated with an Increase Risk of Developing JIA Fail to DOWN Regulate RUNX1 after CELL Stimulation
Abstract Number: 1970

Linking Genetics to T Cell Phenotype in JIA: Rationale for IL-2 Therapy
Abstract Number: 1971

PLCG2 Variants Influence CVID Susceptibility: Expanding the Spectrum of PLCG2-Associated Immune Dysregulation
Abstract Number: 1972

Resolving the Synovial Fluid Proteome and Peptidome for Disease-Specific Mediators of Inflammatory Arthritis
Abstract Number: 1973

Leveraging Publicly Available Gene Expression Data and Applying Machine Learning to Identify Novel Biomarkers for Rheumatoid Arthritis
Abstract Number: 1974

Dynamics of Transcriptional Signatures from Synovial Macrophage Subsets during Acute and Chronic Murine Models of Inflammatory Arthritis
Abstract Number: 1975

Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations
Abstract Number: 1976

Sequencing of the MHC Region Defines HLA-DQA1 As Driven Risk for Anti-Citrullinated Protein Antibodies (ACPA)-Positive Rheumatoid Arthritis in Han Population
Abstract Number: 1977

Transcriptional Perturbation of RA-Risk Enhancer By CRISPR-DEADCAS9 Regulates LONG Range GENE Targets
Abstract Number: 1978

Genome Wide Association Studies in SLE Predict E-Genes and Gene Expression Patterns That Inform Ancestral-Specific Molecular Pathways and Targeted Therapies
Abstract Number: 1979

Rheumatoid Arthritis-Associated Genetic Alteration Defines a New Promoter for Peptydil Arginine Deiminase 4 Gene

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].